Book Value per Share: Innate Pharma S.A. (IPHA)

The financial position of Innate Pharma S.A. (IPHA) relies on volatile payments from strategic partners, with the key metric currently at -0.49. Historical price action illustrates the business's dependence on the development of immune-based oncology drugs. Simultaneously, the company adheres to bioethical standards and environmental regulations within its laboratories. However, the risk of early-stage research halts and cash flow volatility exert significant pressure on the company's market capitalization.

IPHA: Innate Pharma, S.A. Net Asset Value per Share 07/04/2022 - 10/27/2026

innate-pharma.com - analytical breakdowns and key metrics (IPHA)

- price and consensus price forecast:

Stock Price Innate Pharma, S.A.|IPHA - Fair Value Consensus

- market capitalization data:

Market Capitalization Innate Pharma S.A.|IPHA - Enterprise Value

- book capitalization data:

Net Assets per Single Share Innate Pharma|IPHA - Total Stockholders' Equity|Market Value to Book Value Ratio innate-pharma.com|IPHA - Total Business Assets

- debt and liquidity data:

Total Debt to Capital Innate Pharma S.A.|IPHA - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Innate Pharma|IPHA - Company Cumulative Debt|Debt to Book Capitalization Ratio Innate Pharma S.A.

Fundamental company valuation:IPHA - Innate Pharma, S.A.

Investors utilize equity analysis to identify hidden asset impairments and assess the actual coverage of each security. For Innate Pharma S.A. (IPHA), which relies on milestone payments from Sanofi and AstraZeneca, the net asset value per share demonstrates the actual value of capital minus liabilities, allowing a distinction between real financial backing and inflated "paper" capital.

Competitor analysis for Innate Pharma S.A.